lvrachЛечащий ВрачLechaschi Vrach1560-51752687-1181ООО «Издательство "Открытые системы"»10.51793/OS.2025.28.9.006lvrach-1464Research ArticleАКТУАЛЬНАЯ ТЕМАTOPICAL THEMEЦитокиногенетическая терапия в комбинированном лечении рака толстого кишечникаCytokine therapy in combination treatment of colorectal cancerhttps://orcid.org/0000-0002-7973-5231ЗаркуаВ. Т.ZarkuaV. T.

Заркуа Владимир Тамазиевич, онколог

125047, Москва, ул. Фадеева, 4

Researcher ID (WOS): NFS – 4512-2025

Vladimir T. Zarkua, oncologist

4 Fadeev St., Moscow, 125047

Researcher ID (WOS): NFS – 4512-2025

miro.zarkua@gmail.comhttps://orcid.org/0000-0001-9239-2539Бен АммарА. М.Ben AmmarА. M.

Бен Аммар Амир Мохамед, онколог

125047, Москва, ул. Фадеева, 4

Researcher ID (WOS): NFS – 7043-2025

Аmir M. Ben Ammar, oncologist

4 Fadeev St., Moscow, 125047

Researcher ID (WOS): NFS – 7043-2025

amirbenammar94095@gmail.comСпирочкинаЕ. Э.SpirochkinaE. E.

Спирочкина Елена Эдуардовна, онколог

125047, Москва, ул. Фадеева, 4

Elena E. Spirochkina, oncologist

4 Fadeev St., Moscow, 125047

alena.dudka2016@yandex.ruОнкоКейр Клиник 308РоссияOncoCare Clinic 308Russian Federation202524092025093641Copyright © Заркуа В.Т., Бен Аммар А.М., Спирочкина Е.Э., 20252025Заркуа В.Т., Бен Аммар А.М., Спирочкина Е.Э.Zarkua V.T., Ben Ammar А.M., Spirochkina E.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.lvrach.ru/jour/article/view/1464Введение

Введение. Лечение колоректального рака на поздних линиях лекарственной терапии представляет значительные сложности, поскольку арсенал возможностей противоопухолевой терапии ограничен. Для потенцирования действия повторно назначаемых цитостатиков привлекает возможность использования препаратов цитокиногенетической терапии.

Цель работы

Цель работы. Оценить у пациента с IV стадией прогрессирующего рака толстого кишечника эффективность и безопасность применения цитокиногенетической терапии в сочетании с цитостатической терапией в поздней линии противоопухолевого лечения.

Материал и методы

Материал и методы. Под наблюдением находился пациент 62 лет, поступивший с первично-множественным синхронным раком толстой кишки: рак поперечно-ободочной кишки, усТ3N2M1b (печень), оперативное вмешательство (27.09.2022), 4 линии терапии (FOLFOX-6, FOLFIRI + бевацизумаб, регорафиниб, цетуксимаб), прогрессия, рак прямой кишки рТ2N0M0, оперативные вмешательства (18.06.2020, 27.09.2022). При обследовании была использована магнитно-резонансная томография с контрастным усилением.

Результаты

Результаты. Пациент отметил улучшение самочувствия после трех курсов цитокиногенетической терапии, а после восьмого курса смог не только выполнять привычную работу по дому и самостоятельно добираться до больницы, но и стал немного заниматься своей профессиональной деятельностью. Применение противоопухолевой терапии по схеме ХЕLOX (пятая линия) в сочетании с цитокиногенетической терапией не сопровождалось выраженной токсичностью. По данным магнитно-резонансной томографии была достигнута частичная регрессия опухолевых очагов.

Заключение

Заключение. Совместное использование полихимиотерапии по схеме ХЕLOX и препаратов цитокиногенетической терапии позволило достичь частичной регрессии ранее прогрессирующей опухоли и увеличить продолжительность жизни больного.

Background

Background. Treatment of colorectal cancer in late lines of drug therapy presents significant challenges, since the arsenal of antitumor therapy options is limited. The possibility of using cytokinogenetic therapy drugs is attractive for potentiating the effect of re-administered cytostatics.

Objective

Objective. To evaluate the efficacy and safety of cytokinogenetic therapy in combination with cytostatic therapy in a patient with stage IV progressive colon cancer in the late line of antitumor treatment.

Material and methods

Material and methods. A 62-year-old patient was observed, admitted with a diagnosis of primary multiple synchronous colon cancer: transverse colon cancer, usT3N2M1b (liver), surgery (09/27/2022), 4 lines of therapy (FOLFOX-6, FOLFIRI + bevacizumab, regorafinib, cetuximab), progression, rectal cancer pT2N0M0, surgery (06/18/2020, 09/27/2022). During the examination, magnetic resonance imaging (MRI) with contrast enhancement was used.

Results

Results. The patient noted an improvement in his well-being after three courses of cytokinogenetic therapy, and after the 8th course he was able not only to do his usual housework and get to the hospital on his own, but also began to do his professional activities a little. The use of antitumor therapy according to the XELOX scheme (5th line) in combination with cytokinogenetic therapy was not accompanied by significant toxicity. According to MRI data, partial regression of tumor foci was achieved.

Conclusion

Conclusion. The combined use of polychemotherapy according to the XELOX scheme and cytokinogenetic therapy drugs made it possible to achieve partial regression of a previously progressing tumor and increase the patient's life expectancy.

колоректальный ракпоздние линии лекарственной терапиицитокиногенетическая терапияцитостатикиcolorectal cancerlate-line drug therapycytokinogenetic therapycytostaticsReferencesCho Y. A., Lee J., Oh J. H., et al. Genetic Risk Score, Combined Lifestyle Factors and Risk of Colorectal Cancer. Cancer Res Treat. 2019; 51 (3): 1033-1040. https://doi.org/10.4143/crt.2018.447.Cho Y. A., Lee J., Oh J. H., et al. Genetic Risk Score, Combined Lifestyle Factors and Risk of Colorectal Cancer. Cancer Res Treat. 2019; 51 (3): 1033-1040. https://doi.org/10.4143/crt.2018.447.Baidoun F., Elshiwy K., Elkeraie Y., et al. Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes. Curr. Drug Targets. 2021; 22 (9): 9981009. https://doi.org/10.2174/1389450121999201117115717.Baidoun F., Elshiwy K., Elkeraie Y., et al. Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes. Curr. Drug Targets. 2021; 22 (9): 9981009. https://doi.org/10.2174/1389450121999201117115717.Beets-Tan R. G. H., Lambregts D. M. J., Maas M., et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur. Radiol. 2018; 28 (4): 1465-1475. https://doi.org/10.1007/s00330-017-5026-2.Beets-Tan R. G. H., Lambregts D. M. J., Maas M., et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur. Radiol. 2018; 28 (4): 1465-1475. https://doi.org/10.1007/s00330-017-5026-2.Гришко П. Ю., Балясникова С. С., Самсонов Д. В., Мищенко А. В., Карачун А. М., Правосудов И. В. Современный взгляд на принципы диагностики и лечения рака прямой кишки по данным МРТ (обзор литературы). Medical Visualization. 2019; 23 (2): 7-26. https://doi.org/10.24835/1607-0763-2019-2-7-26.Grishko P. Yu., Balyasnikova S. S., Samsonov D. V., Mishchenko A. V., Karachun A. M., Pravosudov I. V. Modern view on the principles of diagnostics and treatment of rectal cancer according to MRI data (literature review). Medical Visualization. 2019; 23 (2): 7-26. (In Russ.) https://doi. org/10.24835/1607-0763-2019-2-7-26.Mödl B., Moritsch S., Zwolanek D., Eferl R. Type I and II interferon signaling in colorectal cancer liver metastasis. Cytokine. 2023; 161: 156075. https://doi.org/10.1016/j.cyto.2022.156075.Mödl B., Moritsch S., Zwolanek D., Eferl R. Type I and II interferon signaling in colorectal cancer liver metastasis. Cytokine. 2023; 161: 156075. https://doi.org/10.1016/j.cyto.2022.156075.Zeng X., Ward S. E., Zhou J., Cheng A. S. L. Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives. Cancers (Basel). 2021; 13 (10): 2418. https://doi.org/10.3390/cancers13102418.Zeng X., Ward S. E., Zhou J., Cheng A. S. L. Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives. Cancers (Basel). 2021; 13 (10): 2418. https://doi.org/10.3390/ cancers13102418.Tang Y., Wei J., Ge X., Yu C., Lu W., Qian Y., Yang H., Fu D., Fang Y., Zhou X., Wang Z., Xiao Q., Ding K. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer. Cancer Letters. 2024; 588: 216798. https://doi.org/10.1016/j.canlet.2024.216798.Tang Y., Wei J., Ge X., Yu C., Lu W., Qian Y., Yang H., Fu D., Fang Y., Zhou X., Wang Z., Xiao Q., Ding K. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer. Cancer Letters. 2024; 588: 216798. https://doi.org/10.1016/j.canlet.2024.216798.Чепорова М. С., Чепоров С. В., Трякин А. А. Выбор лечения химиорефрактерного рака толстой кишки. Злокачественные опухоли. 2023; 13 (3): 56-63. https://doi.org/10.18027/2224-5057-2023-13-3-56-63.Cheporova M. S., Cheporov S. V., Tryakin A. A. Choice of treatment for chemorefractory colon cancer. Malignant tumors. 2023, 13 (3): 56-63. (In Russ.) https://doi.org/10.18027/2224-5057-2023-13-3-56-63.Modest D. P., Pant S., Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur. J. Cancer. 2019; 109: 70-83. https://doi.org/10.1016/j.ejca.2018.12.019.Modest D. P., Pant S., Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur. J. Cancer. 2019; 109: 70-83. https://doi.org/10.1016/j.ejca.2018.12.019.Mauri G., Gori V., Bonazzina E. Oxaliplatin retreatment in metastatic colorectal cancer : Systematic review and future research opportunities. Cancer Treat Rev. 2020; 91: 102112. https://doi.org/10.1016/j.ctrv.2020.102112.Mauri G., Gori V., Bonazzina E. Oxaliplatin retreatment in metastatic colorectal cancer : Systematic review and future research opportunities. Cancer Treat Rev. 2020; 91: 102112. https://doi.org/10.1016/j.ctrv.2020.102112.Zhang X., Wu T., Cai X., et al. Neoadjuvant Immunotherapy for MSI-H / dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Front Immunol. 2022; 17 (13): 795972. https://doi.org/10.3389/fimmu.2022.795972.Zhang X., Wu T., Cai X., et al. Neoadjuvant Immunotherapy for MSI-H / dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Front Immunol. 2022; 17 (13): 795972. https://doi.org/10.3389/fimmu.2022.795972.Teng H.-W., Wang T.-Y., Lin C.-C., et al. Interferon Gamma Induces Higher Neutrophil Extracellular Traps Leading to Tumor-Killing Activity in Microsatellite Stable Colorectal Cancer. Mol Cancer Ther. 2024; 23 (7): 1043-1056. https://doi.org/10.1158/1535-7163.MCT-23-0744.Teng H.-W., Wang T.-Y., Lin C.-C., et al. Interferon Gamma Induces Higher Neutrophil Extracellular Traps Leading to Tumor-Killing Activity in Microsatellite Stable Colorectal Cancer. Mol Cancer Ther. 2024; 23 (7): 1043-1056. https://doi.org/10.1158/1535-7163.MCT-23-0744.Wang Y., Lu J., Huang D., et al. Explosive tumor growth in a patient with colon cancer is associated with reduced neoantigen levels and decreased interferon-gamma (IFN-γ) signaling. BMC Cancer. 2025; 25: 1005. https://doi.org/10.1186/s12885-025-14211-y.Wang Y., Lu J., Huang D., et al. Explosive tumor growth in a patient with colon cancer is associated with reduced neoantigen levels and decreased interferon-gamma (IFN-γ) signaling. BMC Cancer. 2025; 25: 1005. https://doi.org/10.1186/s12885-025-14211-y.Schwartzberg L., Houghton J., Phillips D., et al. Phase II, biomarker and genomic correlative study of GFL: Interferon gamma (IFN-γ), bolus/infusion 5-FU and leucovorin (LV) for metastatic colorectal cancer (mCRC). Cancer Res. 2008; 68 (9_Supplement): 4456.Schwartzberg L., Houghton J., Phillips D., et al. Phase II, biomarker and genomic correlative study of GFL: Interferon gamma (IFN-γ), bolus/infusion 5-FU and leucovorin (LV) for metastatic colorectal cancer (mCRC). Cancer Res. 2008; 68 (9_Supplement): 4456.Sha L., Zhang H., Zhang X. Thymosin α1 combined with XELOX improves immune function and reduces serum tumor markers in colorectal cancer patients after radical surgery. Open Life Sci. 2024; 19 (1): 20220793. https://doi.org/10.1515/biol-2022-0793Sha L., Zhang H., Zhang X. Thymosin α1 combined with XELOX improves immune function and reduces serum tumor markers in colorectal cancer patients after radical surgery. Open Life Sci. 2024; 19 (1): 20220793. https://doi.org/10.1515/biol-2022-0793Ke L., Zhou J., Mao W., et al. Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG) Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial. Intensive Care Med. 2022; 48 (7): 899-909. https://doi.org/10.1007/s00134-022-06745-7.Ke L., Zhou J., Mao W., et al. Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG) Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial. Intensive Care Med. 2022; 48 (7): 899-909. https://doi.org/10.1007/s00134-022-06745-7.Илюшин А. Л., Бен Аммар А. М. Случай успешного лечения рака поджелудочной железы. Российский онкологический журнал. 2022; 27 (5): 243-250. DOI: https://doi.org/10.17816/onco456482.Ilyushin A. L., Ben Ammar A. M. A case of successful treatment of pancreatic cancer. Russian journal of oncology. 2022; 27 (5): 243-250. (In Russ.) https://doi.org/10.17816/onco456482.

The authors declare that there are no conflicts of interest present.